Sign Up to like & get
recommendations!
1
Published in 2018 at "Acta Diabetologica"
DOI: 10.1007/s00592-018-1246-4
Abstract: Nivolumab, an Immune Checkpoint Inhibitor (ICI) against programmed death-1 receptors expressed on T-lymphocytes, has been approved by the Food and Drug Administration (FDA) for the treatment of multiple cancers such as Nonsquamous Cell Lung Cancer…
read more here.
Keywords:
fulminant type;
induced fulminant;
first italian;
nivolumab induced ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2019 at "Journal of Diabetes Investigation"
DOI: 10.1111/jdi.13143
Abstract: We describe here a case of nivolumab‐induced type 1 diabetes, which developed within 9 days of treatment. The case highlights the importance of frequent monitoring of glucose after initiation of nivolumab treatment.
read more here.
Keywords:
fulminant type;
induced fulminant;
diabetes precipitous;
type diabetes ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Experimental Biology and Medicine"
DOI: 10.1177/15353702221126562
Abstract: Fulminant hepatitis remains a critical health problem owing to its high mortality rate and the lack of effective therapies. An increasing number of studies have shown that glutamine supplementation provides protective benefits in inflammation-related disorders,…
read more here.
Keywords:
glutamine lipopolysaccharide;
induced fulminant;
lps gal;
hepatitis ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Experimental Animals"
DOI: 10.1538/expanim.20-0014
Abstract: The metabolic sensor sirtuin 1 (SIRT1) also functions as a checkpoint in inflammation, and SRT1720 is a highly active and selective SIRT1 activator shown to alleviate inflammatory injury in several recent experimental studies. In the…
read more here.
Keywords:
fulminant hepatitis;
activator srt1720;
induced fulminant;
srt1720 ... See more keywords